PP
STSA

PDT Partners’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

PDT Partners’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$70K – 1055
2021
Q3 		$70K Sell
15,000
-24,525
-62% -$130K 0.01% 745
2021
Q2 		$279K Sell
39,525
-20,465
-34% -$110K 0.02% 627
2021
Q1 		$355K Sell
59,990
-7,110
-11% -$43.1K 0.03% 575
2020
Q4 		$309K Buy
67,100
+50,931
+315% +$220K 0.02% 539
2020
Q3 		$63K Buy
+16,169
New +$325K ﹤0.01% 698

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PDT Partners's STSA Position: Q4 2021 in Review

PDT Partners sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2021, closing a stake of 15,000 shares — an estimated $70K sold.

PDT Partners first reported a position in STSA in Q3 2020 and held it in 5 quarters. The position peaked at $355K in Q1 2021. 35 funds tracked by Wall St. Rank hold STSA as of Q4 2021.

  • PDT Partners reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • PDT Partners sold 15,000 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $70K.
  • PDT Partners first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • PDT Partners's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $355K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on PDT Partners's 13F filing for Q4 2021, filed 14 Feb 2022.